Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 3 data of Revefenacin for COPD due fourth quarter 2016

Source Link:: http://investor.theravance.com/releasedetail.cfm?ReleaseID=941670

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

TBPH

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details
Revefenacin: Two Phase 3 efficacy studies in COPD (2016)

http://investor.ther...

Additional Relevant Details We anticipate the revefenacin Phase 3 program in COPD will read out data from the replicate three-month efficacy studies early in the fourth quarter of this year

http://investor.ther...

Additional Relevant Details Update on 07/19/17: Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)

http://investor.ther...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Oct 20, 2016

Occurred Source:

http://investor.theravance.com/releasedetail.cfm?ReleaseID=994556

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Revefenacin, Copd